Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.

COM:ADAPTIMMUNE

Adaptimmune Therapeutics plc

Last Close

0.64

22/11 21:00

Market Cap

169.29M

Beta: -

Volume Today

1.34M

Avg: -